SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Lundin Erik) "

Sökning: WFRF:(Lundin Erik)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Andersson, Anton, et al. (författare)
  • Design of a Foiling Optimist
  • 2018
  • Ingår i: Journal of Sailboat Technology. ; 2018, s. 1-24
  • Tidskriftsartikel (refereegranskat)abstract
    • Because of the successful application of hydrofoils on the America's Cup catamarans in the past two campaigns the interest in foiling sailing craft has boosted. Foils have been fitted to a large number of yachts with great success, ranging from dinghies to ocean racers. An interesting question is whether one of the slowest racing boats in the world, the Optimist dinghy, can foil, and if so, at what minimum wind speed. The present paper presents a comprehensive design campaign to answer the two questions. The campaign includes a newly developed Velocity Prediction Program (VPP) for foiling/non-foiling conditions, a wind tunnel test of sail aerodynamics, a towing tank test of hull hydrodynamics and a large number of numerical predictions of foil characteristics. An optimum foil configuration is developed and towing tank tested with satisfactory results. The final proof of the concept is a successful on the water test with stable foiling at a speed of 12 knots.
  •  
2.
  • Axell, Erik, et al. (författare)
  • Coexistence of Speech and Best Effort Services in Enhanced Uplink WCDMA
  • 2005
  • Ingår i: in Proc. of Radiovetenskap och Kommunikation (RVK).
  • Konferensbidrag (refereegranskat)abstract
    • <p>An evaluation of the performance of coexistent voice and best effort data users in Enhanced Uplink WCDMA is studied in this paper. The main focus is on deriving the capacity regions and compare with previous WCDMA releases. It is shown that the Enhanced Uplink yields a large capacity gain in many aspects for all fractions of voice users compared to previous WCDMA releases. It is also shown, by the cumulative distribution functions of noise rise at the capacity limits, that the best effort data users experience bad quality at lower noise rise than voice users. This means that the capacity is in fact limited by the best effort users.</p>
  •  
3.
  •  
4.
  • Hallqvist, Andreas, et al. (författare)
  • Dose escalation to 84 Gy with concurrent chemotherapy in stage III NSCLC appears excessively toxic : Results from a prematurely terminated randomized phase II trial
  • 2018
  • Ingår i: Lung Cancer. - Elsevier. - 0169-5002 .- 1872-8332. ; 122, s. 180-186
  • Tidskriftsartikel (refereegranskat)abstract
    • <p><strong>Objectives</strong>: Concurrent chemoradiotherapy is the mainstay treatment for NSCLC stage III disease. To investigate whether radiation dose escalation based on individual normal tissue constraints can improve outcome, the Swedish lung cancer study group launched this randomized phase II trial.</p><p><strong>Materials and Methods</strong>: NSCLC patients with stage III disease, good performance status (0-1) and adequate lung function (FEV1 &gt; 1.0 L and CO diffusion capacity &gt; 40%) received three cycles of cisplatin (75 mg/m(2) day 1) and vinorelbine (25 mg/m(2) day 1 and 8) every third week. Radiotherapy started concurrently with the second cycle, with either 2 Gy daily, 5 days a week, to 68 Gy (A) or escalated therapy (B) based on constraints to the spinal cord, esophagus and lungs up to 84 Gy by adding an extra fraction of 2 Gy per week.</p><p><strong>Results</strong>: A pre-planned safety analysis revealed excessive toxicity and decreased survival in the escalated arm, and the study was stopped. Thirty-six patients were included during 2011-2013 (56% male, 78% with adenocarcinoma, 64% with PS 0 and 53% with stage IIIB). The median progression-free survival (PFS) and overall survival (OS) were 11 and 17 months in arm B compared to the encouraging results of 28 and 45 months in the standard arm. The 1- and 3-year survival rates were 56% and 33% (B) and 72% and 56% (A), respectively. There were seven toxicity-related deaths due to esophageal perforations and pneumonitis: five in the escalated group and two with standard treatment.</p><p><strong>Conclusion</strong>: Dose-escalated concurrent chemoradiotherapy to 84 Gy to primary tumor and nodal disease is hazardous, with a high risk of excessive toxicity, whereas modern standard dose chemoradiotherapy with proper staging given in the control arm shows a promising outcome with a median survival of 45 months and a 3-year survival of 56% (NCT01664663).</p>
  •  
5.
  • Hallqvist, Andreas, et al. (författare)
  • Dose escalation to 84 Gy with concurrent chemotherapy in stage III NSCLC appears excessively toxic : Results from a prematurely terminated randomized phase II trial
  • 2018
  • Ingår i: Lung Cancer. - 0169-5002 .- 1872-8332. ; 122, s. 180-186
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Objectives: Concurrent chemoradiotherapy is the mainstay treatment for NSCLC stage III disease. To investigate whether radiation dose escalation based on individual normal tissue constraints can improve outcome, the Swedish lung cancer study group launched this randomized phase II trial.</p><p>Materials and Methods: NSCLC patients with stage III disease, good performance status (0–1) and adequate lung function (FEV1 &gt; 1.0 L and CO diffusion capacity &gt; 40%) received three cycles of cisplatin (75 mg/m2 day 1) and vinorelbine (25 mg/m2 day 1 and 8) every third week. Radiotherapy started concurrently with the second cycle, with either 2 Gy daily, 5 days a week, to 68 Gy (A) or escalated therapy (B) based on constraints to the spinal cord, esophagus and lungs up to 84 Gy by adding an extra fraction of 2 Gy per week.</p><p>Results: A pre-planned safety analysis revealed excessive toxicity and decreased survival in the escalated arm, and the study was stopped. Thirty-six patients were included during 2011–2013 (56% male, 78% with adenocarcinoma, 64% with PS 0 and 53% with stage IIIB). The median progression-free survival (PFS) and overall survival (OS) were 11 and 17 months in arm B compared to the encouraging results of 28 and 45 months in the standard arm. The 1- and 3-year survival rates were 56% and 33% (B) and 72% and 56% (A), respectively. There were seven toxicity-related deaths due to esophageal perforations and pneumonitis: five in the escalated group and two with standard treatment.</p><p>Conclusion: Dose-escalated concurrent chemoradiotherapy to 84 Gy to primary tumor and nodal disease is hazardous, with a high risk of excessive toxicity, whereas modern standard dose chemoradiotherapy with proper staging given in the control arm shows a promising outcome with a median survival of 45 months and a 3-year survival of 56% (NCT01664663).</p>
  •  
6.
  • Jemt, Anders, 1985-, et al. (författare)
  • Evaluation of methods for whole genome and transcriptome sequencing from nanograms of FFPE samples
  • ????
  • Annan publikation (övrigt vetenskapligt)abstract
    • <p>The most widely used method for the preservation of clinical tissue specimens is formalin fixation and paraffin embedding (FFPE). Simultaneous analysis of RNA and DNA from samples preserved using this method have long proved problematic, primarily due to lack of material. Here, we describe an attempt to build a complete analysis package for RNA and DNA extracted from single tissue sections. The workflow includes quality control of the extracted material, library preparation and data analysis. We extract DNA with varying integrity from FFPE sections and subject them to whole genome sequencing using two library preparation methods, Illumina TruSeq Nano using the Illumina NeoPrep and Rubicon Genomics ThruPlex. We are able to obtain some usable data, albeit with high duplication rates, demonstrating both the possibilities and challenges of sequencing damaged DNA. Two different approaches to transcriptome sequencing are assessed, the TruSeq RNA Access library preparation kit from Illumina and the SMARTer Stranded Total RNA-Seq Kit - Pico Input from Clonetech. The sequence capture approach of the TruSeq kit is shown to be more robust to low integrity RNA compared to the SMARTer kit. However, the SMARTer kit needs much less starting material and is able to yield data about all transcripts, not just protein coding mRNA.</p>
  •  
7.
  • Kindlund, Bert, 1969-, et al. (författare)
  • CD4(+) regulatory T cells in gastric cancer mucosa are proliferating and express high levels of IL-10 but little TGF-β.
  • 2017
  • Ingår i: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. - 1436-3291. ; 20:1
  • Tidskriftsartikel (refereegranskat)abstract
    • An increase of regulatory T cells, defined as CD25(high)- and/or FOXP3(+)-expressing CD4(+) T cells, within tumors has been reported in several studies. Tregs promote tumor growth by modulating the antitumor immune response, mainly through inhibition of T-cell-mediated tumor cell killing: this has been suggested to be dependent on IL-10 and/or TGF-β. In stomach cancer, the mechanisms behind the accumulation of Tregs in tumor tissue has not been fully elucidated, and neither has Treg gene expression in situ.
  •  
8.
  • Lundin, Catarina, et al. (författare)
  • Clinical and genetic features of pediatric acute lymphoblastic leukemia in Down syndrome in the Nordic countries
  • 2014
  • Ingår i: Journal of Hematology & Oncology. - BioMed Central (BMC). - 1756-8722. ; 7
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Children with Down syndrome (DS) have an increased risk for acute lymphoblastic leukemia (ALL). Although previous studies have shown that DS-ALL differs clinically and genetically from non-DS-ALL, much remains to be elucidated as regards genetic and prognostic factors in DS-ALL. Methods: To address clinical and genetic differences between DS-ALL and non-DS-ALL and to identify prognostic factors in DS-ALL, we ascertained and reviewed all 128 pediatric DS-ALL diagnosed in the Nordic countries between 1981 and 2010. Their clinical and genetic features were compared with those of the 4,647 B-cell precursor (BCP) ALL cases diagnosed during the same time period. Results: All 128 DS-ALL were BCP ALL, comprising 2.7% of all such cases. The 5-year event-free survival (EFS) and overall survival (OS) were significantly (P = 0.026 and P = 0.003, respectively) worse for DS-ALL patients with white blood cell counts >= 50 x 10(9)/l. The age distributions varied between the DS and non-DS cases, with age peaks at 2 and 3 years, respectively; none of the DS patients had infant ALL (P = 0.029). The platelet counts were lower in the DS-ALL group (P = 0.005). Abnormal karyotypes were more common in non-DS-ALL (P < 0.0001), and there was a significant difference in the modal number distribution, with only 2% high hyperdiploid DS-ALL cases (P < 0.0001). The 5-year EFS and 5-year OS were significantly worse for DS-ALL (0.574 and 0.691, respectively) compared with non-DS-ALL (0.783 and 0.894, respectively) in the NOPHO ALL-1992/2000 protocols (P < 0.001). Conclusions: The present study adds further support for genetic and clinical differences between DS-ALL and non-DS-ALL.
9.
  • Lundin, Catarina, et al. (författare)
  • High frequency of BTG1 deletions in acute lymphoblastic leukemia in children with down syndrome.
  • 2012
  • Ingår i: Genes, Chromosomes and Cancer. - John Wiley and Sons Inc.. - 1045-2257. ; 51, s. 196-206
  • Tidskriftsartikel (refereegranskat)abstract
    • Previous cytogenetic studies of myeloid and acute lymphoblastic leukemias in children with Down syndrome (ML-DS and DS-ALL) have revealed significant differences in abnormality patterns between such cases and acute leukemias in general. Also, certain molecular genetic aberrations characterize DS-related leukemias, such as GATA1 mutations in ML-DS and deregulation of the CRLF2 gene in DS-ALL. Whether microdeletions/microduplications also vary between DS and non-DS cases is presently unclear. To address this issue, we performed single nucleotide polymorphism array analyses of eight pediatric ML-DS and 17 B-cell precursor DS-ALL. In the ML-DS cases, a total of 29 imbalances (20 gains and nine losses) and two partial uniparental isodisomies (pUPDs) were detected. None of the 11 small (defined as <10 Mb) imbalances were recurrent, nor were the pUPDs, whereas of the 18 large aberrations, three were recurrent-dup(1q), +8 and +21. In contrast, several frequent changes were identified in the DS-ALL cases, which harbored 82 imbalances (30 gains and 52 losses) and four pUPDs. Of the 40 large changes, 28 were gains and 12 losses, with +X, dup(Xq), dup(1q), del(7p), dup(8q), del(9p), dup(9p), del(12p), dup(17q), and +21 being recurrent. Of the 40 microdeletions identified, several targeted specific genes, with the following being repeatedly deleted: BTG1 and CDKN2A/B (29% of cases), ETV6, IKZF1, PAX5 and SERP2 (18%), and BTLA, INPP4B, P2RY8, and RB1 (12%). Loss of the SERP2 and INPP4B genes, encoding the stress-associated endoplasmic reticulum protein family member 2 and the inositol polyphosphate 4-phosphatase-II, respectively, has previously never been implicated in leukemia. Although deletions of the other genes have been associated with ALL, the high frequency of BTG1 loss is a novel finding. Such deletions may characterize a clinical subgroup of DS-ALL, comprising mainly boys with a high median age. In conclusion, ML-DS and DS-ALL are genetically distinct, with mainly gains in ML-DS and deletions in DS-ALL. Furthermore, DS-ALL is characterized by several recurrent gene deletions, with BTG1 loss being particularly frequent. © 2011 Wiley Periodicals, Inc.
  •  
10.
  • Lundin, Erik, et al. (författare)
  • Scintigraphic assessment of slow transit constipation with special reference to right- or left-sided colonic delay
  • 2004
  • Ingår i: Colorectal Disease. - 1462-8910 .- 1463-1318. ; 6:6, s. 499-505
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>OBJECTIVE: Subtotal colectomy and ileorectal anastomosis for slow transit constipation has several side-effects. The motor abnormality in some patients may be segmental which could motivate a limited resection of the colon. Therefore a diagnostic tool to identify a segmental colonic motor dysfunction is needed. The aim of this study was to evaluate a scintigraphic method to assess colonic transit with special reference to right- or left-sided delay. METHODS: Twenty-three constipated patients (19 women, mean age 50 years) with slow colonic transit on radio-opaque marker studies and 13 healthy individuals (11 women, mean age 46 years) were studied. All subjects were examined with oral (111)Indium-DTPA scintigraphy. The scintigraphic results for patients and controls were presented as geometric centre of radioactivity and percent activity over time in the right, the left and the recto-sigmoid colon. The inter-observer variation in the interpretation of the scans was also evaluated. RESULTS: There was no difference in transit time between the groups of patients and controls in the right colon whereas the patients had a significant delay in the left colon (P &lt; 0.05). Two patients had a marked delay in the right colon followed by relatively rapid transit in the left colon. The inter-observer correlation was good comparing the right, the left and the recto-sigmoid colon (r = 0.58-0.98, P &lt; 0.01-0.001). CONCLUSION: The results indicate that colonic scintigraphy with oral (111)Indium-DTPA may help to select patients for a left or, in a few cases, a right hemicolectomy for slow transit constipation.</p>
  •  
Skapa referenser, mejla, bekava och länka
Åtkomst
fritt online (49)
Typ av publikation
tidskriftsartikel (150)
konferensbidrag (50)
rapport (18)
annan publikation (10)
bokkapitel (7)
doktorsavhandling (6)
visa fler...
licentiatavhandling (1)
visa färre...
Typ av innehåll
refereegranskat (172)
övrigt vetenskapligt (93)
populärvet., debatt m.m. (4)
Författare/redaktör
Rosendahl, Erik, (68)
Lundin-Olsson, Lille ... (67)
Gustafson, Yngve, (40)
Nyberg, Lars, (26)
Gunnarsson, Fredrik, (25)
Geijer Lundin, Erik, (24)
visa fler...
Lindelöf, Nina, (24)
Littbrand, Håkan, (24)
Gustafsson, Fredrik, (14)
Giesler, Reiner, (10)
Nordgren, Ann (10)
Håglin, Lena (9)
Åberg, Anna Cristina ... (9)
Karlsson, Jan (8)
Lundin, Johan, (8)
Brown, Barry, (8)
Graf, Wilhelm, (8)
Karlbom, Urban (8)
Forestier, Erik (7)
Johansson, Bertil, (7)
Lundin, Samuel B, 19 ... (7)
Friesland, Signe (7)
Berg, Lars-Erik (7)
Nyman, Jan (7)
Näsvall, Joakim, (6)
Andersson, Dan I., (6)
Reizenstein, Johan, (6)
Persson, Andreas, (6)
Eriksson, Staffan, (6)
Palmqvist, Lars (6)
Rost, Mattias (6)
Hellström Muhli, Ull ... (6)
Olefeldt, David (5)
Ekberg, Lars (5)
Lundin, Stefan, 1953 ... (5)
Kjellén, Elisabeth (5)
Nilsson, Per (5)
Holmquist, Lars Erik ... (5)
Houltz, Erik, 1951-, (5)
Lewin, Freddi, (5)
Ask, Anders, (5)
Backman, Anders (5)
Maxhall, Marcus, (5)
Sondell, Björn, (5)
Bark, Gunnar, (5)
Brun, Eva, (5)
Stenvall, Michael, (5)
Franzen, Lars (5)
Conradsson, Mia, (5)
Lymer, Gustav (5)
visa färre...
Lärosäte
Umeå universitet (50)
Luleå tekniska universitet (38)
Uppsala universitet (34)
Linköpings universitet (30)
Lunds universitet (24)
Göteborgs universitet (21)
visa fler...
Kungliga Tekniska Högskolan (10)
Stockholms universitet (9)
Karolinska Institutet (8)
Chalmers tekniska högskola (6)
Örebro universitet (4)
Högskolan i Skövde (4)
Högskolan i Jönköping (3)
Södertörns högskola (3)
Mittuniversitetet (2)
Gymnastik- och idrottshögskolan (2)
RISE (2)
Högskolan Dalarna (2)
Mälardalens högskola (1)
Ersta Sköndal Bräcke högskola (1)
Sveriges Lantbruksuniversitet (1)
visa färre...
Språk
Engelska (212)
Svenska (20)
Odefinierat språk (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (107)
Naturvetenskap (59)
Teknik (42)
Samhällsvetenskap (11)
Lantbruksvetenskap (2)
Humaniora (2)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy